COVID-19 Research

The Wisnivesky Lab is at the forefront of studying the long-term outcomes of SARS-CoV-2 infection, leading the Mount Sinai Health System Post-Covid-19 Registry since 2020. In 2021, Dr. Wisnivesky joined the NIH REsearching COVID to Enhance Recovery (RECOVER) Initiative to conduct a Phase II cohort study to examine the incidence and prevalence of sequelae of SARS-CoV-2 infection and a CDC funded project conducting retrospective health record review to describe the clinical features of patients who have visited Mount Sinai’s Center for Post-COVID Care. In 2021, Dr. Wisnivesky received funding from Regeneron Pharmaceuticals to conduct a prospective study examining the extent, quality and durability of immune responses of immunocompromised patients to SARS-CoV-2 compared to control patients without immunodeficiency.

Observational Chronic Illness Prospective Cohort Research

The laboratory conducts both observational and pilot intervention studies in asthma and COPD morbidity. In these studies, we investigate quality of life, symptom perception, disease beliefs, medication adherence, and the intersection of these domains with chronic comorbidities. We utilize validated survey instruments, lung function tests, biomarker analyses, and self-management behavior tracking devices to inform the pilot interventions in these studies with the aim of improving both self-management and outcomes in these populations.

Lung Cancer Outcomes Research

Additionally, there are several projects that are examining outcomes of lung cancer patients with data from national cancer registries. The goal in these studies is to develop treatment recommendations and inform the development of guidelines to improve patient outcomes.